RT Journal Article
SR Electronic
T1 Teratogenic Effect of Radotinib: Case Report
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 6599
OP 6601
VO 36
IS 12
A1 JUYOUNG CHEON
A1 JUNG WHAN AHN
A1 KYUNG MIN PARK
A1 GUISERA LEE
A1 YUN SUNG JO
YR 2016
UL http://ar.iiarjournals.org/content/36/12/6599.abstract
AB Background: Simultaneous presentation of pregnancy and chronic myeloid leukemia (CML) is rare. Tyrosine kinase inhibitors (TKIs) are rarely used in pregnancy. There is almost no information on the effect of recently developed TKIs on the fetus. Case Report: A 22-year-old woman became pregnant while using radotinib, a novel TKI for CML. She was concerned about the possible teratogenic effect of radotinib; hence the first pregnancy was terminated. The patient underwent full-term delivery at the second pregnancy. The infant had facial deformity and congenital laryngomalacia. Conclusion: We witnessed structural abnormality when the patient used radotinib during the first trimester of pregnancy. When radotinib is prescribed for women of childbearing age, thorough education about contraception is necessary.